


Market for brain cancer

- **Glioblastoma** the most frequent malignant cancer
- **Meningioma** the most frequent non-malignant cancer
- The **key benefits** for precise surgery are:
 - Increase likelihood of surviving
 - Decrease re-surgery and/or more aggressive treatment and hospital costs
 - Decrease risk of disability



Source: US-data, doi: [10.3322/caac.21693](https://doi.org/10.3322/caac.21693)

Key figures for FG001 in brain cancer

- **ABG:**

- Likelihood of approval: 33%
- Price (USD): 5,700
- Development costs: MEUR 40
- Doses sold (peak year): 58,000

- **Redeye**

- Likelihood of approval: 18%
- Price (USD): 7,000 - 10,000
- Development costs: MEUR 10 (assumed sold to partner)
- Doses sold (peak year): 10,000

- **SEB**

- Likelihood of approval: 20%
- Price (USD): 6,500 - 10,000
- Development costs: NA
- Doses sold (peak year): 12,000

- **FluoGuide:**

- Glioblastoma incidence per year:
 - US and EU5: 25.000
- Meningioma incidence per year:
 - US and EU5: 65.000
- Price (USD): 4-8,000